SciELO - Scientific Electronic Library Online

 
vol.33 número2Análisis de las prescripciones y dispensaciones de psicofármacos en una oficina de farmacia de la provincia de Mendoza, ArgentinaEventos adversos a medicamentos relacionados a adequações posológicas índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista de la OFIL

versão On-line ISSN 1699-714Xversão impressa ISSN 1131-9429

Resumo

GONZALEZ-FRANCO, RM; GOMEZ-GOMEZ, D  e  VALERO-DOMINGUEZ, M. Introduction of anti-TNF biosimilars and economic impact in a third level hospital. Rev. OFIL·ILAPHAR [online]. 2023, vol.33, n.2, pp.134-140.  Epub 04-Mar-2024. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2023000200007.

Objectives:

To analyze the introduction of first-line anti-TNF biosimilar drugs for patients with rheumatoid arthritis (RA).

Methods:

Single-center, retrospective, observational study in a tertiary hospital. Patients with a diagnosis of RA treated for the first time with a biologic drug (biosimilar or original) between February 2017-February 2021 were included. The outcome variables collected were: percentage of patients initiating treatment each year with each biologic drug and percentage of annual variation in the use of anti-TNF drugs that had a biosimilar with respect to the other alternatives.

Results:

178 patients diagnosed with RA were treated for the first time with a biologic drug. During the first two years of the introduction of biosimilars, the percentage of RA patients treated first line with adalimumab, infliximab and etanercept was 23.9%, while in the last two years prescriptions with these drugs increased, despite the appearance of new originals, so that during the last year of the study they covered 44.6% of prescriptions. The use of these three biosimilar anti-TNF drugs in patients with RA has resulted in savings of 213,530 €.

Conclusions:

In our center, the use of anti-TNF biosimilars has been consolidated in the last two years, despite the incorporation of new originals in the treatment of RA. Considering the different existing biosimilar introduction policies, it would be interesting to carry out similar studies in other regions of our country in order to establish which biosimilar use policy may be more accepted.

Palavras-chave : Biosimilar; tumor necrosis factor inhibitors; rheumatoid arthritis; adalimumab; infliximab; etanercept.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )